The potential clinical relevance of visible particles in parenteral drugs

Journal of Pharmaceutical Sciences

Volumn 101, Issue 8, 2012, Pages 2635-2644

  Doessegger, Lucette ^a   Mahler, Hanns Christian ^a   Szczesny, Piotr ^a   Rockstroh, Helmut ^a   Kallmeyer, Georg ^b   Langenkamp, Anja ^a   Herrmann, Joerg ^c   Famulare, Joseph ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c GENENTECH INC   (United States)

Author keywords

Distribution; Injectables; Particle size; Particles; Physicochemical properties; Precipitation; Regulatory science; Thromboembolism; Toxicity

Indexed keywords

ALUMINUM DERIVATIVE; CALCIUM PHOSPHATE; DIAMORPHINE; GLUTAMATE SODIUM; IMMUNOGLOBULIN; MICROSPHERE; PARENTERAL SOLUTION; TALC;

AGE; ARTICLE; ARTIFICIAL EMBOLISM; CARCINOGENICITY; COTTON; DEATH; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM; DRUG MANUFACTURE; DRUG SAFETY; GRANULOMA; HUMAN; IMMUNOGENICITY; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ABUSE; LUNG COMPLICATION; LUNG EMBOLISM; LUNG GRANULOMA; NONHUMAN; PARADOXICAL EMBOLISM; PARTICLE SIZE; PARTICULATE MATTER; PHLEBITIS; PULMONARY ARTERY OCCLUSION; RESPIRATORY DISTRESS; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; TOTAL PARENTERAL NUTRITION;

EID: 84862899884     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23217     Document Type: Review

References (68)

1. Shabushnig JG. 2005. Visual inspection-More than separating good from bad. New England Chapter of the Parenteral Drug Association.
2. Shabushnig JG. 2009. Lifting the fog around the visual inspection of injectable products. Dinner Meeting. West Coast Chapter Parenteral Drug Association.
3. USP. 1995. United States Pharmacopeia. XXIIIrd ed. United States Pharmacopeial Convention.
4. Mahler HC, Friess W, Grauschopf U, Kiese S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98:2909-2934.
5. Turco SJ. 1994. Sterile dosage forms. 4th ed. Philadelphia: Lea and Febiger.
6. Narhi LO, Schmit J, Bechtold-Peters K, Sharma D. 2012. Classification of protein aggregates. J Pharm Sci 101:493-498.
7. 2011. Monoclonal antibodies for human use (2031). Pharmeuropa 23:601-602. Accessed April 16, 2012. Available at:
8. EFPIA. 2009. Proposed acceptance criteria for visible particles in parenteral solutions for submission to EDQM. Draft EFPIA proposal for comments.
9. Akers MJ, Larrimore DS, Morton-Guazzo D. 2010. Particulate matter testing. Parenteral quality control, sterility, pyrogen, particulate, and package integrity testing. 3rd ed. New York: Marcel Dekker Inc. p 198.
10. Ahuja S, Scypinski S. 2001. Handbook of modern pharmaceutical analysis, volume 3 (Separation science and technology). San Diego: Academic Press.
11. Leversee RL, Shabushnig JG. 2008. A survey of industry practice for the visual inspection of injectable products (preliminary report). PDA Visual Inspection Forum.
12. European Medicines Evaluation Agency. 2008. European Pharmacopoeia 6.0, Parenteral preparations, injections, European Directorate for the quality of medicines and healthcare. Strasbourg, France: EMEA. p 736.
13. Madsen RE, Cherris RT, Shabushnig JG, Hunt DG. 2009. Visible particulates in injections-A history and a proposal to revise USP general chapter injections (1). Pharm Forum 35:1383-1387.
14. Society of Japanese Pharmacopoeia. 2006. Japanese Pharmacopoeia. 15 ed. General rules for preparations, 11. Injections. 11 ed. Tokyo, Japan: Japanese Pharmacopoeia.
15. Lee KR, Chae YJ, Cho SE, Chung SJ. 2011. A strategy for reducing particulate contamination on opening glass ampoules and development of evaluation methods for its application. Drug Dev Ind Pharm 37:1394-1401.
16. Jorens PG, Van ME, Snoeckx A, Parizel PM. 2009. Nonthrombotic pulmonary embolism. Eur Respir J 34:452-474.
17. FDA. 2009. Update on particulate matter in blood bags. U.S. Food and Drug Administration. Accessed April 10, 2012. Available at:
18. McKinnon BT. 1996. FDA safety alert: Hazards of precipitation associated with parenteral nutrition. Nutr Clin Pract 11:59-65.
19. Hill SE, Heldman LS, Goo ED, Whippo PE, Perkinson JC. 1996. Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. JPEN J Parenter Enteral Nutr 20:81-87.
20. Shay DK, Fann L, Jarvis WR. 1997. Respiratory distress and sudden death associated with receipt of a peripheral parenteral nutrition admixture. Infect Control Hosp Epidemiol 18(12):814-817.
21. Knowles JB, Cusson G, Smith M, Sitrin MD. 1989. Pulmonary deposition of calcium phosphate crystals as a complication of home total parenteral nutrition. JPEN J Parenter Enteral Nutr 13:209-213.
22. Reedy JS, Kuhlman JE, Voytovich M. 1999. Microvascular pulmonary emboli secondary to precipitated crystals in a patient receiving total parenteral nutrition: A case report and description of the high-resolution CT findings. Chest 115:892-895.
23. Hopkins GB. 1972. Pulmonary angiothrombotic granulomatosis in drug offenders. JAMA 221:909-911.
24. Arnett EN, Battle WE, Russo JV, Roberts WC. 1976. Intravenous injection of talc-containing drugs intended for oral use. A cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med 60:711-718.
25. Douglas FG, Kafilmout KJ, Patt NL. 1971. Foreign particle embolism in drug addicts: Respiratory pathophysiology. Ann Intern Med 75:865-880.
26. Tuovinen L, Peltonen S, Liikola M, Hotakainen M, Lahtela-Kakkonen M, Poso A, Jarvinen K. 2004. Drug release from starch-acetate microparticles and films with and without incorporated alpha-amylase. Biomaterials 25:4355-4362.
27. Jr. Tomashefski JF, Hirsch CS. 1980. The pulmonary vascular lesions of intravenous drug abuse. Hum Pathol 11:133-145.
28. Brown KT. 2004. Fatal pulmonary complications after arterial embolization with 40-120-microm tris-acryl gelatin microspheres. J Vasc Interv Radiol 15:197-200.
29. Avis KE, Lieberman HA, Lachman L. 1993. Pharmaceutical dosage forms parenteral medications. Vol. 2. New York: Marcel Dekker.
30. DeLuca PP, Rapp RP, Bivins B, McKean HE, Griffen WO. 1975. Filtration and infusion phlebitis: A double-blind prospective clinical study. Am J Hosp Pharm 32:1001-1007.
31. Falchuk KH, Peterson L, McNeil BJ. 1985. Microparticulate-induced phlebitis. Its prevention by in-line filtration. N Engl J Med 312:78-82.
32. Liu L, Randolph TW, Carpenter JF. 2010. The effects of particles shed from syringe filters. 12 ed. MFI Poster Hall.
33. Davis NN, Turco S, Sivelly E. 1970. Particulate matter in I.V. infusion fluids. Bull Parenter Drug Assoc 24:257-270.
34. Dando W. 1979. Particulate contamination of parenterals. Anesth Prog 26:127-128.
35. Dougherty L, Bravery K, Gabriel J. 2010. The RCN IV therapy forum 2010 standards for infusion therapy. 3rd ed. London: The Royal College of Nursing.
36. ERBITUX Prescribing Information 2012. Accessed April 10, 2012. Available at:
37. Gil ME, Mateu J. 1998. Treatment of extravasation from parenteral nutrition solution. Ann Pharmacother 32:51-55.
38. Kasdon EJ, Schlossman SF. 1973. An experimental model of pulmonary arterial granulomatous inflammation. Am J Pathol 71:365-372.
39. Passarino G, Ciccone G, Siragusa R, Tappero P, Mollo F. 2005. Histopathological findings in 851 autopsies of drug addicts, with toxicologic and virologic correlations. Am J Forensic Med Pathol 26:106-116.
40. Burton JF, Zawadzki S, Wetherell HR, Moy TW. 1965. Mainliners and blue velvet. J Forensic Sci 10:466-472.
41. Nutescu EA. 2007. Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches. Am J Health Syst Pharm 64:S5-S13.
42. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. 1997. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 126:528-531.
43. Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, Kipp J, Ning J. 2008. Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 60:939-954.
44. Lofthus RM, Srebnik HH. 1987. The physical dimensions of the human neonatal cardiovascular system. J Biomech Eng 109:336-339.
45. Norman M. 2008. Low birth weight and the developing vascular tree: A systematic review. Acta Paediatr 97:1165-1172.
46. Genzel-Boroviczeny O, Christ F, Glas V. 2004. Blood transfusion increases functional capillary density in the skin of anemic preterm infants. Pediatr Res 56:751-755.
47. Reed MJ, Edelberg JM. 2004. Impaired angiogenesis in the aged. Sci Aging Knowledge Environ Feb 18th 2004(7):pe7.
48. Sadoun E, Reed MJ. 2003. Impaired angiogenesis in aging is associated with alterations in vessel density, matrix composition, inflammatory response, and growth factor expression. J Histochem Cytochem 51:1119-1130.
49. Heyman S. 1979. Toxicity and safety factors associated with lung perfusion studies with radiolabeled particles. J Nucl Med 20:1098-1099.
50. Zoller B, Li X, Sundquist J, Sundquist K. 2011. Parental history and venous thromboembolism: A nationwide study of age-specific and sex-specific familial risks in Sweden. J Thromb Haemost 9:64-70.
51. Davis MA, Taube RA. 1978. Pulmonary perfusion imaging: Acute toxicity and safety factors as a function of particle size. J Nucl Med vol 19 n 11:1209-1213.
52. Chiu YK, Huang CC, Jeng J, Shiea J, Chen WJ. 2006. Foreign body granuloma caused by monosodium glutamate after BCG vaccination. J Am Acad Dermatol 55:S1-S5.
53. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8:E501-E507.
54. Knezevic-Maramica I, Kruskall MS. 2003. Intravenous immune globulins: An update for clinicians. Transfusion 43:1460-1480.
55. Barandun S, Kistler P, Jeunet F, Isliker H. 1962. Intravenous administration of human gamma-globulin. Vox Sang 7:157-174.
56. FDA. 2005. Intravenous immune globulins in the 21st century: Progress and challenges in efficacy, safety and paths to licensure. Accessed April 10, 2012. Available at:
57. FDA. 2010. Summary basis for regulatory action-GLASSIA. Accessed April 10, 2012. Available at:
58. De Gregorio E, D'Oro U, Wack A. 2009. Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 21:339-345.
59. Fradkin AH, Carpenter JF, Randolph TW. 2011. Glass particles as an adjuvant: A model for adverse immunogenicity of therapeutic proteins. J Pharm Sci 100:4953-4964.
60. Stein MD. 1999. Medical consequences of substance abuse. Psychiatr Clin North Am 22:351-370.
61. den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W. 2011. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28:920-933.
62. Zolls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, Hawe A. 2012. Particles in therapeutic protein formulations, Part 1: Overview of analytical methods. J Pharm Sci 101:914-935.
63. FDA. 2010. Visible particulates in the final container. Accessed April 4, 2012. Available at:
64. Prinzmetal M, Simkin B. 1948. Studies on the collateral circulation of the normal human heart coronary perfusion with radioactive erythrocytes and glass spheres. Arch Inst Cardiol Mex 18:122-156.
65. Illum L, Davis SS. 1982. The targeting of drugs parenterally by use of microspheres. J Parenter Sci Technol 36:242-248.
66. Wilkins DJ, Myers PA. 1966. Studies on the relationship between the electrophoretic properties of colloids and their blood clearance and organ distribution in the rat. Br J Exp Pathol 47:568-576.
67. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP. 2008. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29:2276-2315.
68. Haworth SG, Hislop AA. 1983. Pulmonary vascular development: Normal values of peripheral vascular structure. Am J Cardiol 52:578-583.